Therapeutic plasma exchange: a paired comparison of Fresenius AS104 vs. COBE Spectra.
For therapeutic plasma exchange (TPE), continuous flow separators are known to be efficient as exemplified by Fresenius AS104 and COBE Spectra. The AS104 uses an interface monitoring system in the centrifuge during TPE, whereas Spectra uses computer algorithms to establish the plasma-cell interface. To determine the plasma collection efficiency (PLCE), anticoagulant (AC) volumes used, and platelets (PLT) lost of the AS104 and the Spectra, we performed a prospective paired comparison of 20 TPE (each machine). The study included 17 patients, 1.3 plasma volume exchanges (without AC), equal inlet rates, and AC ratio of 13:1. Processing times did not include reinfuse mode. Platelet loss was determined by sampling the collection bags. Inlet rates were between 60-110 ml/min. Diagnosis included peripheral neuropathies, TTP and cryoglobulinemia. The AS104 had significantly (P<0.0001) lower average whole blood processed (F:6,601 vs. S:8,584 ml), AC volume (F:532 vs. S:719 ml), and processing time (F:80 vs. S:102 minutes) than Spectra. The AS104 had significantly (P<0.0001) higher average plasma flow rates (F:53 vs. S:44 ml/minute), plasma collection efficiency (F:90 vs. S:69%), and platelet loss (F:2.0 vs. S:0.14 x 10(11) plt) than Spectra. Platelet loss correlated with inlet flow rate with the AS104 but not with the Spectra. The AS104 has a significantly higher collection efficiency than Spectra allowing it to remove the same amount of plasma in significantly less time, by processing significantly less blood, using significantly less AC, but removing significantly more platelets than Spectra.
Burgstaler
E A
EA
Division of Transfusion Medicine, Mayo Clinic, Rochester, Minnesota 55905, USA.
Pineda
A A
AA
D000925:Anticoagulants / Q000008:administration & dosage; D001327:Autoimmune Diseases / Q000097:blood / Q000628:therapy; D003449:Cryoglobulinemia / Q000097:blood / Q000628:therapy; D005260:Female; D020275:Guillain-Barre Syndrome / Q000097:blood / Q000628:therapy; D006400:Hematocrit; D006463:Hemolytic-Uremic Syndrome / Q000097:blood / Q000628:therapy; D006801:Humans; D008297:Male; D009157:Myasthenia Gravis / Q000097:blood / Q000628:therapy; D010951:Plasma Exchange / Q000009:adverse effects / Q000295:instrumentation*; D020277:Polyradiculoneuropathy, Chronic Inflammatory Demyelinating / Q000097:blood / Q000628:therapy; D011697:Purpura, Thrombotic Thrombocytopenic / Q000097:blood / Q000628:therapy; D011897:Random Allocation; D012212:Rheology; D013921:Thrombocytopenia / Q000209:etiology; D013997:Time Factors
D000925:Anticoagulants